You Have an Endometriosis Drug. Now How Do You Test It?
Developing a new endometriosis drug is only half the challenge. The real question is how to prove it works. Discover why human organoid models are transforming preclinical drug discovery beyond animal testing.
White Paper: Redefining Fibroid Research with Human-Derived Cell Models
To advance fibroid research, Opal Therapeutics has developed lab-grown uterine organoids and cells from menstrual effluent and tissue biopsies. These models offer a suite of research tools to closely mimic how fibroids behave in the body and allow researchers to test how different drugs affect both healthy and fibroid-affected cells.
Bringing the NAMs Revolution to Women's Health
How New Approach Methodologies (NAMs) can shift drug discovery and bring powerful advancements in women’s health
Application Note: Human Endometrial Organoids as a New Approach Methodology (NAM) for Preclinical Cytotoxicity Testing in Women’s Reproductive Health
We present patient-derived endometrial organoids as a sensitive and scalable model for reproductive toxicity screening, aligning with FDA and NIH priorities for human-based NAMs.
Future of Biotech: Organoids
The FDA’s shift toward organoid-based and AI-powered drug testing marks a new era in biotech. Opal Therapeutics is leading in women’s health with our uterus-in-a-dish platform—using patient-derived uterine organoids to model diseases like endometriosis and fibroids with human-relevant precision.